FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 386 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR New on NCI’s Websites for December 2021 December 29, 2021 Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says June 2, 2020 NCI Launches New Resource for Specimens and Data from Cancer Clinical... April 2, 2018 If You Let It, Nursing Will Change Your Life May 24, 2021 Load more HOT NEWS Teen Helps Mom With Cancer Shave Her Head, Then Turns To... Test Detects Early Signs of Remaining Cancer in Kids Treated for... Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab... Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast...
